Leading the way to safer medication
 Crosscheck  Recommender

Bezafibrate

Description

Bezafibrate lowers elevated blood lipids (triglycerides and cholesterol). Elevated VLDL and LDL are reduced by treatment with bezafibrate, whilst HDL-levels are increased. Furthermore, cholesterol biosynthesis is reduced by bezafibrate, which is accompanied by a stimulation of the LDL receptor-mediated lipoprotein catabolism.

ATC Classification

Code
Title
Category
C10AB02
Bezafibrate
C Cardiovascular system → C10 Lipid modifying agents → C10A Lipid modifying agents, plain → C10AB Fibrates

Trade names

Trade name
Countries

France

Austria Canada Netherlands United Kingdom

Austria

Spain

Spain

United Kingdom

Cyprus

Cyprus Singapore

Product Monographs

Monograph
Type
Country
BEZAFIBRATE Film-coated tablet
MPI, EU: SmPC
UK